Equities Analysts Offer Predictions for MIST FY2029 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Milestone Pharmaceuticals in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $1.86 per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04.

Milestone Pharmaceuticals Stock Down 1.5 %

MIST stock opened at $2.02 on Tuesday. The firm’s 50-day simple moving average is $1.96 and its 200 day simple moving average is $1.66. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The stock has a market cap of $107.73 million, a PE ratio of -2.49 and a beta of 1.78. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Valeo Financial Advisors LLC grew its position in Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $46,000. Atria Investments Inc boosted its stake in Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the period. Finally, BML Capital Management LLC grew its position in Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.